Drug Profile


Alternative Names: RVX-000222; RVX-208

Latest Information Update: 31 May 2017

Price : $50

At a glance

  • Originator Resverlogix Corporation
  • Class Anti-inflammatories; Cardiovascular therapies; Quinazolines; Small molecules
  • Mechanism of Action Apolipoprotein A I stimulants; Bromodomain and extraterminal domain protein inhibitors; Chemokine CCL2 modulators; Interleukin 6 inhibitors; Vascular cell adhesion molecule modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Acute coronary syndromes; Atherosclerosis; Low HDL cholesterol
  • Phase II Prediabetic-state
  • Phase I Alzheimer's disease
  • Preclinical Renal failure

Most Recent Events

  • 30 May 2017 Health Canada grants approval to conduct a clinical trial in Fabry's disease
  • 30 May 2017 Resverlogix Corporation plans a clinical trial in Fabry's disease in Canada
  • 15 May 2017 The US FDA approves IND application for apabetalone in Renal failure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top